Vivek Subbiah: Final efficacy and safety results of the ROAR phase 2 basket trial of dabrafenib in eight cohorts of patients with BRAFV600E-mutated advanced rare cancers

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on LinkedIn:

“BRAFV600E alterations are prevalent across multiple tumors and is a tissue agnostic precision medicine target. Final efficacy and safety results of the ROAR phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor) in eight cohorts of patients with BRAFV600E-mutated advanced rare cancers:

• Anaplastic thyroid carcinoma (n = 36),
• Biliary tract cancer (n = 43) adenocarcinoma of the small intestine (n = 3),
• Low-grade glioma (n = 13),
• High-grade glioma (n = 45)
• Hairy cell leukemia (n = 55)
• Multiple myeloma (n = 19).
  (both solid+ liquid tumors) – BRAF + Mutiple myeloma as well

Link to Nature Medicine paper.”

Source: Vivek Subbiah/LinkedIn